The burgeoning landscape of treatment for obesity and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant variations in their pharmacological profiles and clinical trial results are emerging. Retatrutide, boa

Arriving in the landscape of weight management therapy, retatrutide is a distinct strategy. Unlike many existing medications, retatrutide operates as a twin agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. The dual engagement fosters various advantageous effects, like improved